Summary: Augurex Life Sciences and ARUP Laboratories have introduced the 14-3-3η test to help detect and manage rheumatoid arthritis, offering improved diagnostic capabilities for early intervention and personalized care.

Takeaways:

  1. The 14-3-3η protein is a crucial biomarker for the early detection of rheumatoid arthritis, associated with severe disease and joint damage.
  2. The test enables clinicians to identify patients at higher risk, allowing for earlier and more personalized treatment strategies.
  3. The partnership with ARUP Laboratories expands access to the 14-3-3η test across the U.S., advancing the early diagnosis and management of RA.

Augurex Life Sciences Corp., a provider in autoimmune biomarker-based diagnostics, announced that ARUP Laboratories, a national reference laboratory, has launched the 14-3-3η test as part of their diagnostic testing portfolio for the detection and management of rheumatoid arthritis (RA).

Detecting Rheumatoid Arthritis

The 14-3-3η protein is a key biomarker for the early detection and management of RA. Elevated levels of 14-3-3η are associated with more severe disease and a higher risk of joint damage, making it an important diagnostic indicator for identifying patients who may benefit from early intervention. As this test becomes more widely available, clinicians gain improved access to diagnostic tools that help identify individuals at greater risk, paving the way for more personalized patient care.

“We are excited to partner with ARUP Laboratories as they incorporate the 14-3-3η test into their diagnostic offerings, reinforcing our commitment to advancing the early diagnosis and treatment of rheumatoid arthritis,” says Neil Klompas, CEO of Augurex. “This collaboration marks a significant milestone in our mission to expand access to the 14-3-3η test for clinicians and patients across the United States, in line with our shared goal of improved health outcomes for those affected with rheumatoid arthritis.”

ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics, the company says.